Skip to main content

ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., June 09, 2020 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Lori Kunkel, M.D., to its board of directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization.
“We are delighted to welcome Lori to our board of directors as ORIC embarks on this next phase of its evolution,” said Jacob Chacko, M.D., chief executive officer. Over a multi-decade career, Lori has made significant contributions as a clinician, academic and highly respected leader in the biotechnology community, and has played a key role in the development, approval and commercialization of multiple innovative oncology therapies.  We look forward to her contributions and insights as we continue to advance our lead asset, ORIC-101, further into clinical development while ORIC-533 and our early stage pipeline progress toward the clinic.”
                                                                                                                                           
Dr. Kunkel currently serves on the board of directors of Nurix Therapeutics, Maverick Therapeutics and Curis, and has served on the board of directors of Loxo Oncology, Amphivena, Harpoon Therapeutics and Tocagen. Previously, she served as acting Chief Medical Officer at Loxo Oncology, as Chief Medical Officer at Pharmacyclics and Proteolix, and in various senior clinical roles at Baxter Healthcare, Chiron, and Genentech. Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at the University of California, Los Angeles. Dr. Kunkel received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.“ORIC Pharmaceuticals is making great strides in advancing its broad pipeline of novel therapies aimed at overcoming resistance in cancer, making this an incredibly exciting time to be joining the board,” said Dr. Kunkel. “I look forward to collaborating with the leadership team and my fellow board members to help ORIC advance its novel therapeutics and further develop its pipeline.”About ORIC Pharmaceuticals, Inc.ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.  ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.  Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to http://oricpharma.com/.Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.